These 5 stocks have the potential to outperform the overall market over time because of their future potential.

They are well-positioned to deliver a high upside to investors over the next 12 to 18 months.

Discover all the details - including name and ticker symbol - here.

SNSE Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 19.90%

Insider Buying (Last 12 Months): $2,065,485.67

Insider Selling (Last 12 Months): $0.00

Sensei Biotherapeutics Insider Trading History Chart

Sensei Biotherapeutics Share Price & Price History

^$1.63

+0.30 (1.20%)

As of 10/6/2022 06:12 PM ET

Days: 30 | 90 | 365

Strong Fundamentals With Huge News

From GRVI Management | Ad

Multiple lucrative verticals and capturing growing markets.

Sensei Biotherapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
3/2/2022	James Peyer	Director	Buy	1,203	$3.20	$3,849.60
3/1/2022	Cambrian Biopharma Inc	Major Shareholder	Buy	2,458	$3.60	$8,848.80
2/28/2022	James Peyer	Director	Buy	42	$3.60	$151.20
2/24/2022	James Peyer	Director	Buy	15,000	$3.63	$54,450.00
2/23/2022	Cambrian Biopharma Inc	Major Shareholder	Buy	2,500	$3.80	$9,500.00
2/18/2022	Cambrian Biopharma Inc	Major Shareholder	Buy	15,000	$3.97	$59,550.00
2/17/2022	James Peyer	Director	Buy	4,949	$4.17	$20,637.33
2/16/2022	Cambrian Biopharma Inc	Major Shareholder	Buy	2,551	$4.25	$10,841.75
2/14/2022	Cambrian Biopharma Inc	Major Shareholder	Buy	10,000	$4.18	$41,800.00
2/11/2022	Cambrian Biopharma Inc	Major Shareholder	Buy	12,500	$4.40	$55,000.00
2/10/2022	James Peyer	Director	Buy	5,000	$4.58	$22,900.00
2/8/2022	Cambrian Biopharma Inc	Major Shareholder	Buy	10,000	$4.33	$43,300.00
2/4/2022	James Peyer	Director	Buy	2,500	$4.45	$11,125.00
2/3/2022	Cambrian Biopharma Inc	Major Shareholder	Buy	17,500	$4.65	$81,375.00
1/28/2022	James Peyer	Director	Buy	8,900	$4.22	$37,558.00
1/27/2022	Cambrian Biopharma Inc	Major Shareholder	Buy	6,100	$4.31	$26,291.00
1/26/2022	James Peyer	Director	Buy	29,900	$4.62	$138,138.00
1/25/2022	Cambrian Biopharma Inc	Major Shareholder	Buy	20,100	$4.86	$97,686.00
1/24/2022	James Peyer	Director	Buy	22,707	$4.69	$106,495.83
1/21/2022	Cambrian Biopharma Inc	Major Shareholder	Buy	24,703	$4.94	$122,032.82
1/20/2022	James Peyer	Director	Buy	20,000	$5.17	$103,400.00
1/19/2022	Cambrian Biopharma Inc	Major Shareholder	Buy	10,244	$4.97	$50,912.68
1/18/2022	James Peyer	Director	Buy	10,000	$5.08	$50,800.00
1/14/2022	Cambrian Biopharma Inc	Major Shareholder	Buy	6,219	$4.99	$31,032.81
1/13/2022	James Peyer	Director	Buy	19,953	$5.13	$102,358.89
1/12/2022	Cambrian Biopharma Inc	Major Shareholder	Buy	9,202	$5.22	$48,034.44
1/11/2022	James Peyer	Director	Buy	10,845	$5.18	$56,177.10
12/29/2021	Cambrian Biopharma Inc	Major Shareholder	Buy	69,000	$4.98	$343,620.00
12/28/2021	James Peyer	Director	Buy	11,288	$5.28	$59,600.64
12/27/2021	Cambrian Biopharma Inc	Major Shareholder	Buy	3,712	$5.30	$19,673.60
12/23/2021	James Peyer	Director	Buy	11,000	$5.27	$57,970.00
12/17/2021	James Peyer	Director	Buy	117	$5.29	$618.93
12/16/2021	Cambrian Biopharma Inc	Major Shareholder	Buy	10,925	$5.25	$57,356.25
12/9/2021	Thomas G. Ricks	Director	Buy	20,000	$6.62	$132,400.00
8/11/2021	Robert Hamilton Pierce	Insider	Sell	16,030	$7.34	$117,660.20
8/9/2021	Robert Hamilton Pierce	Insider	Sell	6,982	$7.06	$49,292.92
8/6/2021	Robert Hamilton Pierce	Insider	Sell	6,460	$7.11	$45,930.60
5/5/2021	Cambrian Biopharma Inc	Major Shareholder	Buy	350	$12.00	$4,200.00
4/20/2021	Cambrian Biopharma Inc	Major Shareholder	Buy	385	$12.77	$4,916.45
4/19/2021	James Peyer	Director	Buy	1,965	$13.38	$26,291.70
4/13/2021	Cambrian Biopharma Inc	Major Shareholder	Buy	2,000	$14.00	$28,000.00
4/7/2021	James Peyer	Director	Buy	2,000	$14.00	$28,000.00
4/1/2021	Cambrian Biopharma Inc	Major Shareholder	Buy	1,000	$14.00	$14,000.00
3/30/2021	Cambrian Biopharma Inc	Major Shareholder	Buy	2,000	$12.00	$24,000.00
3/30/2021	Cambrian Biopharma Inc	Major Shareholder	Buy	2,000	$12.00	$24,000.00
3/24/2021	Cambrian Biopharma Inc	Major Shareholder	Buy	3,750	$14.12	$52,950.00
3/23/2021	James Peyer	Director	Buy	10,000	$14.34	$143,400.00
3/22/2021	Cambrian Biopharma Inc	Major Shareholder	Buy	2,183	$15.02	$32,788.66
3/18/2021	Cambrian Biopharma Inc	Major Shareholder	Buy	817	$15.25	$12,459.25
3/8/2021	James Peyer	Director	Buy	1,000	$15.25	$15,250.00
3/5/2021	Cambrian Biopharma Inc	Major Shareholder	Buy	8,000	$13.75	$110,000.00
2/23/2021	James Peyer	Director	Buy	20,300	$17.79	$361,137.00
2/22/2021	Cambrian Biopharma Inc	Major Shareholder	Buy	9,802	$18.88	$185,061.76

Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast

From Legacy Research | Ad

He predicted the 2020 crash a month before it happened…He predicted this year’s collapse back in January…

And now, he’s issuing a brand-new warning – along with a unique solution.

Details here.

SEC Filings (Institutional Ownership Changes) for Sensei Biotherapeutics (NASDAQ:SNSE)

21.34% of Sensei Biotherapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Sensei Biotherapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
8/15/2022	State Street Corp	25,774	$59K	0.0%	-88.6%	0.084%
8/15/2022	Citadel Advisors LLC	59,380	$0.13M	0.0%	N/A	0.193%
8/15/2022	Millennium Management LLC	133,705	$0.30M	0.0%	+168.8%	0.435%
8/13/2022	Renaissance Technologies LLC	247,000	$0.56M	0.0%	+196.9%	0.806%
8/12/2022	Northern Trust Corp	15,542	$35K	0.0%	-89.9%	0.051%
7/22/2022	Truist Financial Corp	19,934	$45K	0.0%	-60.5%	0.065%
6/7/2022	Bank of America Corp DE	48,001	$0.11M	0.0%	+91.7%	0.157%
5/17/2022	Jane Street Group LLC	10,767	$25K	0.0%	N/A	0.035%
5/16/2022	State Street Corp	225,572	$0.52M	0.0%	+7.3%	0.735%
5/16/2022	UBS Group AG	13,618	$31K	0.0%	-39.2%	0.044%
5/13/2022	Renaissance Technologies LLC	83,195	$0.19M	0.0%	N/A	0.271%
5/12/2022	BlackRock Inc.	1,168,011	$2.70M	0.0%	-2.9%	3.807%
5/12/2022	HighTower Advisors LLC	50,229	$0.12M	0.0%	N/A	0.164%
5/11/2022	Raymond James & Associates	13,000	$30K	0.0%	N/A	0.042%
5/3/2022	Leo Brokerage LLC	14,845	$34K	0.0%	N/A	0.048%
11/16/2021	Millennium Management LLC	258,659	$2.72M	0.0%	N/A	0.846%
11/16/2021	Moore Capital Management LP	49,341	$0.52M	0.0%	-61.3%	0.161%
11/12/2021	Tao Capital Management LP	32,784	$0.35M	0.1%	N/A	0.107%
11/12/2021	The Manufacturers Life Insurance Company	13,478	$0.14M	0.0%	N/A	0.044%
11/12/2021	Geode Capital Management LLC	273,978	$2.88M	0.0%	+93.2%	0.896%
11/10/2021	Citigroup Inc.	2,409	$25K	0.0%	+565.5%	0.008%
11/9/2021	BlackRock Inc.	1,000,322	$10.52M	0.0%	+175.2%	3.270%
11/5/2021	Truist Financial Corp	70,374	$0.74M	0.0%	N/A	0.230%
11/4/2021	Deutsche Bank AG	12,021	$0.13M	0.0%	+158.3%	0.039%
11/1/2021	SG Americas Securities LLC	12,614	$0.13M	0.0%	N/A	0.041%
10/13/2021	BFT Financial Group LLC	14,845	$0.16M	0.0%	N/A	0.049%
8/17/2021	Citadel Advisors LLC	283,667	$2.77M	0.0%	-59.0%	0.927%
8/16/2021	Alyeska Investment Group L.P.	40,000	$0.39M	0.0%	N/A	0.131%
8/16/2021	Tudor Investment Corp Et Al	28,111	$0.27M	0.0%	-75.2%	0.092%
8/16/2021	Charles Schwab Investment Management Inc.	54,965	$0.54M	0.0%	+18.9%	0.180%
8/16/2021	State Street Corp	100,000	$0.98M	0.0%	+70.2%	0.327%
8/13/2021	Formula Growth Ltd.	100,000	$0.98M	0.1%	+77.7%	0.327%
8/13/2021	Northern Trust Corp	75,011	$0.73M	0.0%	-8.5%	0.245%
8/13/2021	Geode Capital Management LLC	141,809	$1.38M	0.0%	+20.8%	0.464%
8/13/2021	Vanguard Group Inc.	387,753	$3.78M	0.0%	+19.4%	1.268%
8/12/2021	JPMorgan Chase & Co.	179,078	$1.75M	0.0%	+15.1%	0.585%
8/11/2021	Bank of New York Mellon Corp	18,431	$0.18M	0.0%	+31.1%	0.060%
8/11/2021	BlackRock Inc.	363,466	$3.55M	0.0%	+9.2%	1.188%
8/11/2021	Deutsche Bank AG	4,653	$45K	0.0%	-73.3%	0.015%
8/2/2021	New York State Common Retirement Fund	5,396	$53K	0.0%	+37.2%	0.018%
5/27/2021	Davidson Kempner Capital Management LP	26,000	$0.38M	0.0%	N/A	0.085%
5/21/2021	Citadel Advisors LLC	692,537	$10.06M	0.0%	N/A	2.264%
5/18/2021	Zimmer Partners LP	46,000	$0.67M	0.0%	N/A	0.150%
5/18/2021	Tudor Investment Corp Et Al	113,353	$1.65M	0.0%	N/A	0.371%
5/18/2021	Duquesne Family Office LLC	100,000	$1.45M	0.0%	N/A	0.327%
5/18/2021	Davidson Kempner Capital Management LP	26,000	$0.38M	0.0%	N/A	0.085%
5/18/2021	Citadel Advisors LLC	692,537	$10.06M	0.0%	N/A	2.264%
5/18/2021	Falcon Edge Capital LP	213,658	$3.10M	0.2%	N/A	0.699%
5/18/2021	California State Teachers Retirement System	11,494	$0.17M	0.0%	N/A	0.038%
5/17/2021	Deerfield Management Company L.P. Series C	375,000	$5.45M	0.1%	N/A	1.226%
5/17/2021	Nuveen Asset Management LLC	12,340	$0.18M	0.0%	N/A	0.040%
5/13/2021	Bank of New York Mellon Corp	14,062	$0.21M	0.0%	N/A	0.046%
5/12/2021	Serengeti Asset Management LP	20,000	$0.29M	0.1%	N/A	0.065%
5/12/2021	Northern Trust Corp	81,947	$1.19M	0.0%	N/A	0.268%
5/12/2021	Geode Capital Management LLC	117,406	$1.71M	0.0%	N/A	0.384%
5/12/2021	Pura Vida Investments LLC	67,357	$0.94M	0.0%	N/A	0.220%
5/12/2021	JPMorgan Chase & Co.	155,647	$2.26M	0.0%	N/A	0.509%
5/12/2021	UBS Group AG	2,099	$31K	0.0%	N/A	0.007%
5/11/2021	New York State Common Retirement Fund	3,934	$57K	0.0%	N/A	0.013%
5/7/2021	BlackRock Inc.	332,700	$4.83M	0.0%	N/A	1.088%
5/7/2021	American International Group Inc.	4,441	$65K	0.0%	N/A	0.015%

Data available starting January 2016

Sensei Biotherapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of immunotherapies with an initial focus on treatments for cancer. It develops proprietary ImmunoPhage platform, an immunotherapy approach that is designed to utilize bacteriophage to induce a focused and coordinated innate and adaptive immune response; and Tumor Microenvironment Activated Biologics, a platform designed to unleash the anti-tumor potential of T-cells, as well as human monoclonal antibodies that are selectively active in the tumor microenvironment and target immune checkpoints or other critical immune pathways. The company also develops SNS-101, a monoclonal antibody for the treatment of cancer; and SNS-401-NG, an ImmunoPhage vaccine targeting multiple tumor antigens. It has a collaboration with The University of Washington to research and develop Merkel cell carcinoma vaccine. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.

Today's Range

Now: $1.63

$1.60

$1.68

50 Day Range

MA: $1.91

$1.55

$2.22

52 Week Range

Now: $1.63

$1.45

$10.10

Volume

55,835 shs

Average Volume

82,198 shs

Market Capitalization

$50.07 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Sensei Biotherapeutics?: Sensei Biotherapeutics' top insider shareholders include:
Cambrian Biopharma Inc (Major Shareholder)
James Peyer (Director)
Robert Hamilton Pierce (Insider)
Thomas G Ricks (Director)
Learn More about top insider investors at Sensei Biotherapeutics.